References
- Trobe J. Optic nerve involvement in dysthyroidsm. Ophthalmology. 1981 Jun;88(6):488–492.
- Pérez-Moreiras JV, Álvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant graves’ orbitopathy. Ophthal Plast Reconstr Surg. 2014 Mar-Apr;30(2):162–167.
- McKeag D, Lane C, Lazarus JH, et al., European Group on Graves’ Orbitopathy (EUGOGO). Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007 Apr;91(4):455–458.
- Hersh D, Kinnar M. Acute dysthyroid optic neuropathy exacerbated by orbital radiotherapy. Orbit. 2014 Oct;33(5):385–387.
- Sellari-Franceschini S, Dallan I, Bajraktari A, et al. Surgical complications in orbital decompression for Graves’ orbitopathy. Acta Otorhinolaryngol Ital. 2016 Aug;36(4):265–274.
- Currò N, Covelli D, Vannucchi G, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014 May;24(5):897–905.
- Kauh CY, Gupta S, Douglas RS, et al. Compressive optic neuropathy and repeat orbital decompression: a case series. Ophthal Plast Reconstr Surg. 2015 Sep-Oct;31(5):385–390.
- Salvi M, Campi I. Medical treatment of graves’ orbitopathy. Horm Metab Res. 2015 Sep;47(10):779–788.
- Gómez Rodríguez L, Cárdenas Aranzana MJ, Avilés Mora C. Effectiveness and safety of tocilizumab in corticoid refractory Graves’ Orbitopathy. Farm Hosp. 2014 Sep 16;38(5):448–450.
- Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010 Dec 13;5(12):e14328.